drugset / Trial / NCT02514213
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.
Timeline
- Start
- 2015-07
- Primary completion
- 2017-12-12
- Completion
- 2017-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INO 5150 | Other / unclassified | 2 mg | Intramuscular |
| Subject | INO 5150 | Other / unclassified | 8.5 mg | Intramuscular |
| Subject | Rocakinogene Sifuplasmid | Vaccine | 1 mg | Intramuscular |